Genentechs deal with Orionis is not its first foray into targeted protein degradation. The company announced a collaboration in 2022 with Chinabased Jemincare to develop an experimental protein degrader for a target linked to prostate cancer, which poured 40 million into a collaboration with PeptiDream  a Japanese drugmaker working on radiopharmaceuticals